Aradigm Corporation announced that Robert A. Reed, PhD has been appointed as Aradigm's Vice President, Regulatory (CMC) and Quality, reporting to Igor Gonda, President and Chief Executive Officer. Dr. Reed joins Aradigm from Celsion Corporation where he was Senior Vice President of CMC and Technical Operations, overseeing CMC Regulatory and Operations for a liposomal delivery system under clinical development for the treatment of primary liver cancer. Dr. Reed has more than 25 years of pharmaceutical industry experience in preclinical, CMC and regulatory activities spanning The Liposome Company, Merck & Company, XenoPort Incorporated and Celsion Corporation.

While at Merck & Co., Dr. Reed directed the CMC activities of many late stage products, such as Crixivan®, Singulair® and Januvia®.